This study documents the variation in the @entity535 neurotransmitter contents during @entity19 parietal cortex development, from embryonic day 13 (E13) until young adulthood, between postnatal day 21 (P21) and P30. @entity2226 , an inhibitory neurotransmitter and neuromodulator, is the most abundant neurotransmitter in the developing neocortex, whereas, at the adult stage, @entity2227 is the more prominent neurotransmitter playing an excitatory role, and @entity1246 is the major inhibitory neurotransmitter. During the proliferative stage of neurogenesis in the @entity19 cerebral cortex, between E13 and E17, relatively high levels of @entity2227 , @entity492 , @entity2226 and @entity2228 were detected, consistent with a possible trophic influence of these neurotransmitters during cortical development prior to synaptogenesis. Between E17 and E19, a significant decline in the contents of these neurotransmitters was observed, consistent with earlier reports of cell death in the ventricular and subventricular zones during this stage of development. During the perinatal period, a progressive increment in @entity2227 level was seen between E21 and P5, and then the values remained constant until the second postnatal week. @entity2227 also decreased by about 25% between P11 and P15, on the other hand, @entity492 diminished by about 20% between @entity69560 . These results were consistent with previous reports of histogenetic cell death during the first 2 postnatal weeks in @entity19 neocortex. @entity1246 increased from the embryonic period until young adulthood, in contrast, the @entity2228 content decreased; thus, in the adult parietal cortex, the @entity1246 content was about 2.6-fold higher than that of @entity2228 . During the first postnatal week, the concentrations of @entity2227 and @entity1246 showed significant increments between @entity41880 , while those of @entity492 and @entity2228 remained constant. During this period, @entity1522 are predominantly excitatory and the cerebral cortex is vulnerable to epileptiform activity; the significant increment in @entity2226 content between @entity69561 suggests a neuroprotective action of @entity2226 against excitotoxicity. At P15, coinciding with the period of maximum cortical synaptogenesis, significant increments in @entity1246 and @entity2228 contents were observed which could be related to the maturation of inhibitory synaptic transmission. At the young adult stage, there was a rise in the levels of both excitatory neurotransmitters, @entity2227 and @entity492 , and a significant reduction in the contents of all three inhibitory neurotransmitters, @entity1246 , @entity2228 and @entity2226 .

Prenatal and postnatal contents of @entity535 neurotransmitters in XXXX parietal cortex.

@entity2226 :: ('MESH:D013654', 'Chemical') :: ['taurine', 'Taurine'] @entity41880 :: ('71853(Tax:10090)', 'Gene') :: ['P0 and P5'] @entity2227 :: ('CHEBI:29987', 'Chemical') :: ['glutamate', 'Glutamate'] @entity1522 :: ('CHEBI:33709', 'Chemical') :: ['amino acids'] @entity1246 :: ('MESH:D005680', 'Chemical') :: ['GABA'] @entity2228 :: ('CHEBI:57305', 'Chemical') :: ['glycine'] @entity535 :: ('CHEBI:33704', 'Chemical') :: ['amino acid'] @entity19 :: ('10090', 'Species') :: ['mouse'] @entity492 :: ('CHEBI:29995', 'Chemical') :: ['aspartate'] @entity69560 :: ('76775;20024', 'Gene') :: ['P7 and P9'] @entity69561 :: ('214601(Tax:10090)', 'Gene') :: ['P0 and P3']
@entity19 :: (10090,Species) :: ['mouse']
